Autopsy report · NCT06713226

Clinical Performance Evaluation of the Hativ P30

“Company's internal decision.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

VUNO Inc.

Sponsor type

Industry

Conditions

Arrhythmia

Interventions

Hativ P30 and 12-lead ECG comparator device

Participants

0

Trials that died the same way

• A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
  “Internal company decision” (92% match in meaning)
• Core Warming of COVID-19 Patients
  “Internal decision” (83% match in meaning)
• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (79% match in meaning)
• A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
  “Internal company decision (non-safety related)” (79% match in meaning)
• A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)
  “Company decision” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.